Genscript Biotech Corporation announced that Ms. Wang Jiafen had tendered resignation from her positions as a non-executive director and a member of the strategy committee of the Company due to the attainment of statutory retirement age, with effect from 5 July 2024; and Dr. Wang Xuehai had tendered resignation from his position as an independent non-executive Director due to his intention to devote more time to other business commitments, with effect from 5 July 2024. The Board further announces that, with effect from 5 July 2024, Ms. Wang ceased to be a member of the Strategy Committee and Dr. Shi Chenyang, an independent non-executive Director of the Company, has been appointed as a new member of the Strategy Committee.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
12.4 HKD | -1.12% |
|
+38.24% | -37.56% |
07-10 | Genscript Biotech to Use 68,054 RSA Shares for Scheme, Over 425 Million Shares Available Under General Mandate | MT |
07-09 | Genscript Biotech Grants Restricted Shares Under Incentive Scheme | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.56% | 3.42B | |
+22.15% | 46.56B | |
+45.94% | 41.67B | |
-2.37% | 41.16B | |
+33.84% | 32.4B | |
-6.35% | 28.1B | |
+20.42% | 28.18B | |
+48.83% | 14.52B | |
+45.00% | 13.74B | |
+0.06% | 12.17B |
- Stock Market
- Equities
- 1548 Stock
- News Genscript Biotech Corporation
- Genscript Biotech Corporation Announces Board and Committee Changes